A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

Here, we explain the facts behind several more of Robert F. Kennedy Jr.’s claims during his two Senate hearings as nominee ...

The Trump administration's "short pause" on communications, expected to end on Feb. 1, has affected FDA updates on food ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Federal regulators have warned a Waco company that its human amniotic products are “unlicensed” and “unapproved,” and that ...

When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

Even a mild infection with COVID-19 can promote clogged arteries, increasing the risk of heart attack in some people, a new ...

Here’s what to know about the Trump administration’s order and which information is still available to California residents.

“It’s unconscionable that more than four years since this began, we still don’t have one FDA-approved drug,” said Meighan ...